Cargando…
Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial
PURPOSE: Colorectal cancer is becoming an increasing concern in the middle-aged population of Iran. This study aimed to compare the preliminary results of short-course and long-course neoadjuvant chemoradiotherapy treatment for rectal cancer patients. MATERIALS AND METHODS: In this clinical trial we...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society for Radiation Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533412/ https://www.ncbi.nlm.nih.gov/pubmed/33012155 http://dx.doi.org/10.3857/roj.2020.00115 |
_version_ | 1783590127817195520 |
---|---|
author | Aghili, Mahdi Khalili, Nastaran Khalili, Neda Babaei, Mohammad Farhan, Farshid Haddad, Peiman Salarvand, Samaneh Keshvari, Amir Fazeli, Mohammad Sadegh Mohammadi, Negin Ghalehtaki, Reza |
author_facet | Aghili, Mahdi Khalili, Nastaran Khalili, Neda Babaei, Mohammad Farhan, Farshid Haddad, Peiman Salarvand, Samaneh Keshvari, Amir Fazeli, Mohammad Sadegh Mohammadi, Negin Ghalehtaki, Reza |
author_sort | Aghili, Mahdi |
collection | PubMed |
description | PURPOSE: Colorectal cancer is becoming an increasing concern in the middle-aged population of Iran. This study aimed to compare the preliminary results of short-course and long-course neoadjuvant chemoradiotherapy treatment for rectal cancer patients. MATERIALS AND METHODS: In this clinical trial we recruited patients with rectal adenocarcinoma located from 5 cm to 15 cm above the anal verge. Patients in group I (short-course) received three-dimensional conformational radiotherapy with a dose of 25 Gy/5 fractions in 1 week plus concurrent XELOX regimen (capecitabine 625 mg/m(2) from day 1–5 twice daily and oxaliplatin 50 mg/m(2) on day 1 once daily). Patients in group II (long-course) received a total dose of 50–50.4 Gy/25–28 fractions for 5 to 5.5 weeks plus capecitabine 825 mg/m(2) twice daily. Both groups underwent consolidation chemotherapy followed by delayed surgery at least 8 weeks after radiotherapy completion. The pathological response was assessed with tumor regression grade. RESULTS: In this preliminary report on complications and pathological response, 66 patients were randomized into two study groups. Mean duration of radiotherapy in groups I and II was 5 ± 1 days (range, 5 to 8 days) and 38 ± 6 days (range, 30 to 58 days). The median follow-up was 18 months. Pathological complete response was achieved in 32.3% and 23.1% of patients in the short-course and long-course groups, respectively (p = 0.558). Overall, acute grade 3 or higher treatment-related toxicities occurred in 24.2% and 22.2% of patients in group I and II, respectively (p = 0.551). No acute grade 4 or 5 adverse events were observed in either group except one grade 4 hematologic toxicity that was seen in group II. Within one month of surgery, no significant difference was seen regarding grade ≥3 postoperative complications (p = 0.333). CONCLUSION: For patients with rectal cancer located at least 5 cm above the anal verge, short-course radiotherapy with concurrent and consolidation chemotherapy and delayed surgery is not different in terms of acute toxicity, postoperative morbidity, complete resection, and pathological response compared to long-course chemoradiotherapy. |
format | Online Article Text |
id | pubmed-7533412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Korean Society for Radiation Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-75334122020-10-14 Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial Aghili, Mahdi Khalili, Nastaran Khalili, Neda Babaei, Mohammad Farhan, Farshid Haddad, Peiman Salarvand, Samaneh Keshvari, Amir Fazeli, Mohammad Sadegh Mohammadi, Negin Ghalehtaki, Reza Radiat Oncol J Original Article PURPOSE: Colorectal cancer is becoming an increasing concern in the middle-aged population of Iran. This study aimed to compare the preliminary results of short-course and long-course neoadjuvant chemoradiotherapy treatment for rectal cancer patients. MATERIALS AND METHODS: In this clinical trial we recruited patients with rectal adenocarcinoma located from 5 cm to 15 cm above the anal verge. Patients in group I (short-course) received three-dimensional conformational radiotherapy with a dose of 25 Gy/5 fractions in 1 week plus concurrent XELOX regimen (capecitabine 625 mg/m(2) from day 1–5 twice daily and oxaliplatin 50 mg/m(2) on day 1 once daily). Patients in group II (long-course) received a total dose of 50–50.4 Gy/25–28 fractions for 5 to 5.5 weeks plus capecitabine 825 mg/m(2) twice daily. Both groups underwent consolidation chemotherapy followed by delayed surgery at least 8 weeks after radiotherapy completion. The pathological response was assessed with tumor regression grade. RESULTS: In this preliminary report on complications and pathological response, 66 patients were randomized into two study groups. Mean duration of radiotherapy in groups I and II was 5 ± 1 days (range, 5 to 8 days) and 38 ± 6 days (range, 30 to 58 days). The median follow-up was 18 months. Pathological complete response was achieved in 32.3% and 23.1% of patients in the short-course and long-course groups, respectively (p = 0.558). Overall, acute grade 3 or higher treatment-related toxicities occurred in 24.2% and 22.2% of patients in group I and II, respectively (p = 0.551). No acute grade 4 or 5 adverse events were observed in either group except one grade 4 hematologic toxicity that was seen in group II. Within one month of surgery, no significant difference was seen regarding grade ≥3 postoperative complications (p = 0.333). CONCLUSION: For patients with rectal cancer located at least 5 cm above the anal verge, short-course radiotherapy with concurrent and consolidation chemotherapy and delayed surgery is not different in terms of acute toxicity, postoperative morbidity, complete resection, and pathological response compared to long-course chemoradiotherapy. The Korean Society for Radiation Oncology 2020-06 2020-06-05 /pmc/articles/PMC7533412/ /pubmed/33012155 http://dx.doi.org/10.3857/roj.2020.00115 Text en Copyright © 2020 The Korean Society for Radiation Oncology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Aghili, Mahdi Khalili, Nastaran Khalili, Neda Babaei, Mohammad Farhan, Farshid Haddad, Peiman Salarvand, Samaneh Keshvari, Amir Fazeli, Mohammad Sadegh Mohammadi, Negin Ghalehtaki, Reza Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial |
title | Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial |
title_full | Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial |
title_fullStr | Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial |
title_full_unstemmed | Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial |
title_short | Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial |
title_sort | short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533412/ https://www.ncbi.nlm.nih.gov/pubmed/33012155 http://dx.doi.org/10.3857/roj.2020.00115 |
work_keys_str_mv | AT aghilimahdi shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial AT khalilinastaran shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial AT khalilineda shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial AT babaeimohammad shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial AT farhanfarshid shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial AT haddadpeiman shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial AT salarvandsamaneh shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial AT keshvariamir shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial AT fazelimohammadsadegh shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial AT mohammadinegin shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial AT ghalehtakireza shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial |